Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/31/2015 09/01/2015 09/02/2015 09/03/2015 09/04/2015 Date
172.19(c) 170.85(c) 176.24(c) 175.28(c) 171.98(c) Last
1 636 494 2 551 121 1 839 507 1 537 796 1 976 274 Volume
-3.73% -0.78% +3.15% -0.54% -1.88% Change
More quotes
Financials ($)
Sales 2015 2 633 M
EBIT 2015 1 135 M
Net income 2015 579 M
Debt 2015 239 M
Yield 2015 -
Sales 2016 3 390 M
EBIT 2016 1 568 M
Net income 2016 987 M
Finance 2016 523 M
Yield 2016 -
PER 2015 67,56
PER 2016 39,63
EV / Sales 2015 15,1x
EV / Sales 2016 11,5x
Capitalization 39 640 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.It focuses on developing products for the treatment of diseases in the... 
Sector
Pharmaceuticals
Calendar
10/22Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS, I
09/04 ALEXION PHARMACEUTICALS : Receives Notification of PDUFA Date Extension for Kanu..
09/03 ALEXION PHARMACEUTICALS : to Present at the 2015 Morgan Stanley Global Healthcar..
09/03 ALEXION PHARMACEUTICALS : EC Grants Marketing Authorization for Kanuma (sebelipa..
09/03 ALEXION PHARMACEUTICALS : EC Grants Marketing Authorization for Strensiq (asfota..
09/01 ALEXION PHARMACEUTICALS : European Commission Grants Marketing Authorization for..
09/01 ALEXION PHARMACEUTICALS : European Commission Grants Marketing Authorization for..
08/18DJOmeros Reports Positive Study Data, Shares Surge
08/18DJOmeros Reports Positive Study Data, Shares Surge
More news
Sector news : Biopharmaceuticals
06:03a HOSPIRA : A $90 million payday for Hospira CEO after sale to Pfizer
06:03a ABBVIE : Drug ads include a lot of warnings -- probably too many, FDA says
06:03a SANOFI : Nothing like a good cry: Contra Costa County's own 'town crier'
More sector news : Biopharmaceuticals
News from SeekingAlpha
09/04 PREMARKET BIOTECH DIGEST : Shorts Targeting Biotech, Anavex's Promise, Zarxio La..
09/04 FDA pushes PDUFA date out three months for Alexion's enzyme replacement thera..
09/02 PREMARKET BIOTECH DIGEST : Anti-CD Antigen Therapy, Geron Files S-3, 3 MAAs In E..
09/01 Alexion Pharma's Kanuma cleared in the EU for ultra-rare inherited metabolic ..
09/01 Alexion Pharma's Strensiq cleared in the EU for ultra-rare metabolic disease


Comments 
Advertisement
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions